Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Savara Inc.
Headquarters: Austin, TX, United States of America
Website: http://savarapharma.com
Year Founded: 2007
Status: Public
Industry Sector: HealthTechnology
CEO: Matthew Pauls, MBA
Number Of Employees: 37
Enterprise Value: $640,880,864
PE Ratio: -5.97
Exchange/Ticker 1: NASDAQ:SVRA
Exchange/Ticker 2: N/A
Latest Market Cap: $447,925,600
BioCentury | Jul 3, 2024
Product Development
Clinical Report: Updates in myasthenia gravis from J&J, Cartesian
Plus: Readouts for Savara, Lyell and Novo Nordisk
BioCentury | Jun 29, 2024
Finance
Public Equity Report: Alumis slides after downsized IPO
Plus: Offerings by Zealand, Savara and Taysha; Savara’s PIPE; Grail reaches NASDAQ after Illumina separation
BioCentury | Aug 3, 2023
Data Byte
July follow-on financings: argenx raised majority of month’s $2.1B total
Ten biopharmas raised a combined $2.1B in July, of which argenx was responsible for nearly $1.3B
BioCentury | Feb 16, 2023
Management Tracks
Chinook names Oxtoby head of commercial
Plus: Asabys promotes two to partner and updates from Savara, TriNetX, Mahana, Curi Bio and more
BioCentury | Nov 14, 2022
Data Byte
A snapshot of the GM-CSF pipeline
GSK’s decision to drop otilimab brings other GM-CSF therapies under focus
BioCentury | Aug 26, 2022
Management Tracks
Leading China biotechs Everest, CStone announce CEO departures
Plus updates from BD, Sema4,
BioCentury | Dec 2, 2021
Management Tracks
Maraganore headlines Arch’s latest crop of venture partners
Plus Five FDA vets join Sidley and updates from AZ, Neurocrine, ADCendo, Ironwood and more
BioCentury | Sep 12, 2020
Management Tracks
New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more
It’s been a busy week for C4 Therapeutics Inc., which hired a new CEO and filed to go public. Andrew Hirsch is joining the protein degradation company from Agios
BioCentury | Nov 20, 2019
Company News
Management tracks: Vifor, Relay, I-Mab, Yumanity, Savara and more
BioCentury | Jun 14, 2019
Clinical News
June 13 Clinical Quick Takes: Roche's Gazyva meets in Phase II for lupus; plus Boehringer/Lilly, Savara and more
Items per page:
1 - 10 of 27